Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: Systematic review and meta-analysis

American Journal of Gastroenterology

Volumn 107, Issue 10, 2012, Pages 1474-1482

  Halpin, Stephen J ^a   Ford, Alexander C ^a,b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; GLUCOCORTICOID; SALAZOSULFAPYRIDINE;

BLOOD CHEMISTRY; CASE CONTROL STUDY; COLON RADIOGRAPHY; CONFIDENCE INTERVAL; CROHN DISEASE; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE SEVERITY; EMBASE; ENTERITIS; GASTROINTESTINAL ENDOSCOPY; HEALTH SURVEY; HUMAN; IRRITABLE COLON; MEDLINE; META ANALYSIS; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; REMISSION; REVIEW; RISK FACTOR; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; ODDS RATIO; PREVALENCE;

EID: 84867099191     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.260     Document Type: Review

References (57)

1. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Agreus L, Talley NJ, Svardsudd K et al. Identifying dyspepsia and irritable bowel syndrome: the value of pain or discomfort, and bowel habit descriptors. Scand J Gastroenterol 2000; 35: 142-51.
3. Jones R, Lydeard S. Irritable bowel syndrome in the general population. Br Med J 1992; 304: 87-90.
4. Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet 1983; 321: 632-4.
5. Sandler RS, Everhart JE, Donowitz M et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-11.
6. American College of Gastroenterology IBS Task Force. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (Suppl I): S1-7.
7. Spiller R, Aziz Q, Creed FEA et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-98.
8. Kappelman MD, Rifas-Shiman SL, Kleinman K et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-9.
9. Loft us Jr EV, Silverstein MD, Sandborn WJ et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1999; 116: 1161-8.
10. Loft us Jr EV, Silverstein MD, Sandborn WJ et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000; 46: 336-43.
11. Loft us CG, Loft us Jr EV, Harmsen WS et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Infl amm Bowel Dis 2007; 13: 254-61.
12. Pimentel M, Chang M, Chow EJ et al. Identifi cation of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol 2000; 95: 3458-62.
13. Barratt SM, Leeds JS, Robinson K et al. Prodromal irritable bowel syndrome may be responsible for delays in diagnosis in patients presenting with unrecognized Crohn's disease and celiac disease, but not ulcerative colitis. Dig Dis Sci 2011; 56: 3270-5.
14. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
15. Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37.
16. Chadwick V, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83.
17. Cremon C, Gargano L, Morselli-Labate AM et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
18. Long MD, Drossman DA. Infl ammatory bowel disease, irritable bowel syndrome, or what?: a challengeto the functional-organic dichotomy. Am J Gastroenterol 2010; 105: 1796-8.
19. Grover M, Herfarth H, Drossman DA. The functional-organic dichotomy: postinfectious irritable bowel syndrome and infl ammatory bowel diseaseirritable bowel syndrome. Clin Gastroenterol Hepatol 2009; 7: 48-53.
20. Colombel J-F, Sandborn WJ, Reinisch W et al. Infl iximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
21. Sands BE, Sandborn WJ, Feagan BG et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008; 135: 400-9.
22. Isgar B, Harman M, Kaye MD et al. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983; 24: 190-2.
23. Keohane J, O'Mahony C, O'Mahony L et al. Irritable bowel syndrome-type symptoms in patients with infl ammatory bowel disease: a real association or refl ection of occult infl ammation? Am J Gastroenterol 2010; 105: 1789-94.
24. Simren M, Axelsson J, Gillberg R et al. Quality of life in infl ammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002; 97: 389-96.
25. Manning AP, Thompson WG, Heaton KW et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 277: 653-4.
26. Drossman DA, Thompson WG, Talley NJ. Identifi cation of sub-groups of functional gastrointestinal disorders. Gastroenterol Int 1990; 3: 159-72.
27. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl II): II43-7.
28. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford htm2009. Accessed 24th May 2012.
29. Higgins JPT, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-60.
30. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
31. Egger M, Davey-Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34.
32. Sterne JA, Sutton AJ, Ioannidis JP et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Br Med J 2011; 343: d4002.
33. Ansari R, Attari F, Razjouyan H et al. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur J Gastroenterol Hepatol 2008; 20: 46-50.
34. Barratt HS, Kalantzis C, Polymeros D et al. Functional symptoms in infl ammatory bowel disease and their potential infl uence in misclassifi cation of clinical status. Aliment Pharmacol Ther 2005; 21: 141-7.
35. Barratt SM, Leeds JS, Robinson K et al. Refl ux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and infl ammatory bowel disease. Eur J Gastroenterol Hepatol 2011; 23: 159-65.
36. Bryant RV, van Langenberg DR, Holtmann GJ et al. Functional gastrointestinal disorders in infl ammatory bowel disease: impact on quality of life and psychological status. J Gastroenterol Hepatol 2011; 26: 916-23.
37. Farrokhyar F, Marshall JK, Easterbrook B et al. Functional gastrointestinal disorders and mood disorders in patients with inactive infl ammatory bowel disease: prevalence and impact on health. Infl amm Bowel Dis 2006; 12: 38-46.
38. Mikocka-Walus AA, Turnbull DA, Andrews JM et al. The eff ect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with infl ammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 475-83.
39. Minderhoud IM, Oldenburg B, Wismeijer JA et al. IBS-like symptoms in patients with infl ammatory bowel disease in remission: relationships with quality of life and coping behavior. Dig Dis Sci 2004; 49: 469-74.
40. Piche T, Ducrotte P, Sabate JM et al. Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn's disease and irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 626-e174.
41. Zaman MS, Robson KM, Lembo AJ. Overlap of irritable bowel syndrome (IBS) symptoms in patients with infl ammatory bowel disease (IBD). Am J Gastroenterol 2002; 97 (Suppl): S284.
42. Berrill J, Ludlow H, Green J. Functional symptoms in infl ammatory bowel disease. J Crohns Colitis 2012; 6 (Suppl 1): S66.
43. Lovell RM, Ford AC. Global prevalence of, and risk factors for, irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-721.e4.
44. La JH, Kim TW, Sung TS et al. Visceral hypersensitivity and altered colonic motility aft er subsidence of infl ammation in a rat model of colitis. World J Gastroenterol 2003; 9: 2791-5.
45. van Hoboken EA, Thijssen AY, Verhaaren R et al. Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity. Scand J Gastroenterol 2011; 46: 981-7.
46. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety and depression: a meta-analytic review. Psychosom Med 2003; 65: 528-33.
47. Ford AC, Forman D, Bailey AG et al. Irritable bowel syndrome: a 10-year natural history of symptoms, and factors that infl uence consultation behavior. Am J Gastroenterol 2008; 103: 1229-39.
48. Schirbel A, Reichert A, Roll S et al. Impact of pain on health-related quality of life in patients with infl ammatory bowel disease. World J Gastroenterol 2010; 16: 3168-77.
49. Ford AC, Spiegel BMR, Talley NJ et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 1279-86.
50. Ford AC, Chey WD, Talley NJ et al. Yield of diagnostic tests for celiac disease in subjects with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med 2009; 169: 651-8.
51. Wedlake L, A'Hern R, Russell D et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30: 707-17.
52. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected infl ammatory bowel disease: diagnostic metaanalysis. Br Med J 2010; 341: c3369.
53. Kane SV, Sandborn WJ, Rufo PA et al. Fecal lactoferrin is a sensitive and specifi c marker in identifying intestinal infl ammation. Am J Gastroenterol 2003; 98: 1309-14.
54. Poullis AP, Zar S, Sundaram KK et al. A new, highly sensitive assay for C-reactive protein can aid the diff erentiation of infl ammatory bowel disorders from constipation-and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002; 14: 409-12.
55. Ford AC, Talley NJ, Spiegel BMR et al. Effect of fi bre, antispasmodics, and peppermint oil in irritable bowel syndrome: systematic review and meta-analysis. Br Med J 2008; 337: 1388-92.
56. Ford AC, Talley NJ, Schoenfeld PS et al. Effi cacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
57. Moayyedi P, Ford AC, Brandt LJ et al. The effi cacy of probiotics in thetreatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-32.